Literature DB >> 8841143

A biologically active form of chromium may activate a membrane phosphotyrosine phosphatase (PTP).

C M Davis1, K H Sumrall, J B Vincent.   

Abstract

Chromium is essential for proper carbohydrate and lipid metabolism in mammals, although the mechanism of this action has previously proved elusive. Low-molecular-weight chromium-binding protein (LMWCr), a biologically active form of chromium in mammals, potentiates the effect of insulin on the conversion of glucose into lipid and into carbon dioxide in isolated adipocytes. Kinetics studies indicate that LMWCr isolated from bovine liver activates phosphotyrosine phosphatase (PTP) activity in adipocyte membranes while having no intrinsic phosphatase activity. This activation is directly proportional to the amount of added LMWCr. The pattern of inhibition of this activity in the presence of a number of known phosphatase inhibitors suggests the involvement of a membrane phosphotyrosine phosphatase similar to PTP1A' or PTP1B. We propose that chromium plays a biological role in the activation of a membrane phosphotyrosine phosphatase.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8841143     DOI: 10.1021/bi960328y

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

1.  Isolation and characterization of low-molecular-weight chromium-binding substance (LMWCr) from chicken liver.

Authors:  Margarita Viera; C Michele Davis-McGibony
Journal:  Protein J       Date:  2008-09       Impact factor: 2.371

Review 2.  Molecular mechanisms of chromium in alleviating insulin resistance.

Authors:  Yinan Hua; Suzanne Clark; Jun Ren; Nair Sreejayan
Journal:  J Nutr Biochem       Date:  2012-04       Impact factor: 6.048

Review 3.  Current concepts about chromium supplementation in type 2 diabetes and insulin resistance.

Authors:  Zhong Q Wang; William T Cefalu
Journal:  Curr Diab Rep       Date:  2010-04       Impact factor: 4.810

4.  Characterization of the organic component of low-molecular-weight chromium-binding substance and its binding of chromium.

Authors:  Yuan Chen; Heather M Watson; Junjie Gao; Sarmistha Halder Sinha; Carolyn J Cassady; John B Vincent
Journal:  J Nutr       Date:  2011-05-18       Impact factor: 4.798

5.  Metabolic pathways of carcinogenic chromium.

Authors:  Elena Gaggelli; Francesco Berti; Nicola D'Amelio; Nicola Gaggelli; Gianni Valensin; Lucia Bovalini; Alessandro Paffetti; Lorenza Trabalzini
Journal:  Environ Health Perspect       Date:  2002-10       Impact factor: 9.031

6.  Chromium supplementation in non-obese non-diabetic subjects is associated with a decline in insulin sensitivity.

Authors:  Umesh Masharani; Christine Gjerde; Shelley McCoy; Betty A Maddux; Danielle Hessler; Ira D Goldfine; Jack F Youngren
Journal:  BMC Endocr Disord       Date:  2012-11-30       Impact factor: 2.763

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.